Eisai Files for Earlier use of Halaven® (Eribulin) for the Treatment of Metastatic Breast Cancer PR Newswire HATFIELD, England, May 7, 2013 HATFIELD, England, May 7, 2013 /PRNewswire/ -- Eisai today announced that it has filed a Type II Variation application with the European Medicines Agency (EMA) for Halaven (eribulin), requesting an indication extension to include treatment of earlier line metastatic breast cancer (MBC) patients. Eribulin is the first and only single-agent therapy proven to significantly extend overall survival after two prior lines of MBC therapy when compared to other single-agent therapies. Results from a pivotal Phase III study (EMBRACE) demonstrated a statistically significant median overall survival benefit for women treated with eribulin compared with a single-agent treatment of physician's choice (TPC). ^ Eribulin is currently indicated in Europe for the treatment of women with locally advanced or MBC who have previously received at least two chemotherapeutic regimens. Prior therapy should have included an anthracycline and a taxane unless women were not suitable for these treatments. ^[ ^2] Eisai is dedicated to discovering, developing and producing innovative oncology therapies that can make a difference and impact the lives of women and their families. This passion for people is part of Eisai's human health care (hhc) mission, which strives for better understanding of the needs of patients and their families to increase the benefits health care provides. Notes to Editors Halaven ^® (eribulin) Eribulin is a non-taxane, microtubule dynamics inhibitor indicated for the treatment of patients with breast cancer who have previously received at least two chemotherapeutic regimens for metastatic disease and whose prior therapy should have included an anthracycline and a taxane. ^[ ^2 ^] Eribulin belongs to a class of antineoplastic agents, the halichondrins, which are natural products, isolated from the marine sponge Halichondria okadai. It is believed to work by inhibiting the growth phase of microtubule dynamics without affecting the shortening phase and sequesters tubulin into non-productive aggregates. Halaven is approved in the European Union, USA, Russia, Switzerland, South Korea, Japan, and Singapore. Halaven has received pricing authorisation and has launched in Austria, Canada, Denmark, Finland, France, Germany, Iceland, Italy, Luxembourg, Norway, Sweden, Switzerland, Slovenia, and the UK. Global Phase III Study 301 ^ Study 301 was an open-labelled, randomised, two-parallel-arm, multicentre study of Halaven (eribulin) versus capecitabine in 1,102 women with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes, either in the (neo) adjuvant setting or for locally advanced or metastatic disease. This study was outside of the licensed indication for eribulin. Patients in the study received zero to two previous chemotherapies for advanced disease. Global Phase III Clinical Study 305 (EMBRACE) ^[ ^1 ^] EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Treatment of Physician's Choice (TPC) Versus Eribulin E7389) was an open-label, randomised, global, multi-centre, parallel two-arm study designed to compare overall survival in patients treated with eribulin versus a Treatment of Physician's Choice (TPC) arm. TPC was defined as any single-agent chemotherapy, hormonal treatment or biologic therapy approved for the treatment of cancer; or palliative treatment or radiotherapy administered according to local practice. The study included 762 patients with metastatic breast cancer who previously had been treated with at least two and a maximum of five prior chemotherapies, including an anthracycline and a taxane. The vast majority (96%) of patients in the TPC arm received chemotherapy. In the total Phase III EMBRACE study population, eribulin was shown to prolong median overall survival in heavily pre-treated patients with metastatic breast cancer compared to patients receiving TPC by 2.5 months compared to patients receiving TPC (eribulin 13.1 months vs. TPC 10.6 months p=0.041). An updated analysis, demonstrated a statistically significant improvement of 2.7 months (13.2 vs 10.5 HR 0.81 (95% CI 0.067, 0.96) nominal p=0.014). A pre-planned analysis of patients from Region 1 of the study (North America/Western Europe/Australia) showed a significant overall survival benefit of eribulin over TPC of 3.0 months (p=0.031). The most commonly reported adverse reactions among patients treated with eribulin in the EMBRACE study were fatigue (asthenia), a decrease in infection-fighting white blood cells (neutropaenia), hair loss (alopecia), numbness and tingling in arms and legs (peripheral neuropathy), nausea and constipation. Peripheral neuropathy was the most common adverse event leading to discontinuation from eribulin, occurring in less than 5% of the patients involved in the EMBRACE trial. Neutropaenia only led to eribulin discontinuation for 0.6% patients. Death due to serious side effects, discontinuation and dose interruptions to treatment were lower in the eribulin arm of the trial compared with the TPC arm. Metastatic Breast Cancer Over 300,000 women are diagnosed with breast cancer in Europe every year, of whom about one third subsequently develop metastatic disease. ^ ^, ^ Metastatic disease is an advanced stage of the disease that occurs when cancer spreads beyond the breast to other parts of the body. Eisai in Oncology Our commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, therapeutic vaccines, and biologic and supportive care agents for cancer across multiple indications. About Eisai Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies. Eisai concentrates its R&D activities in three key areas: *Oncology including: anticancer therapies; tumour regression, tumour suppression, antibodies, etc. *Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss *Vascular/Immunological reaction including: thrombocytopenia, rheumatoid arthritis, psoriasis, inflammatory bowel disease With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. From its Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business operations to include Europe, the Middle East, Africa and Russia (EMEA). Eisai EMEA has sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands, Belgium, the Middle East and Russia. For further information please visit our web site http://www.eisai.co.uk References 1. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. The Lancet. 2011; 377: 914-923 2. SPC Halaven (updated November 2012). Available at: http://www.medicines.org.uk/emc/medicine/24382 . Last accessed January 2013 3. Kaufman P, Awada A, Twelves C et al. A Phase III, open-label, randomised, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Presented at 2012 CTRC-AACR San Antonio Breast Cancer Symposium 4. World Health Organization. Atlas of Health in Europe. 2003. World Health Organization, Regional Office of Europe, Copenhagen, Denmark. 5. Cancer Research UK. Breast cancer incidence statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence/#world [ http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence ]. Last accessed 03 December 2012. Date of preparation: May 2013 Halaven-UK0120 Contact: Media Enquiries: Eisai Europe Ltd, Charlotte Andrews / Cressida Robson, +44(0)7908-314-155, +44 (0)7947 231513, Cressida_Robson@eisai.net, Charlotte_andrews@eisai.net; Tonic Life Communications, Siobhan Reilly / April Kenneally, +44(0)207-798-9999 / +44(0)784-047-3199, +44(0)207-798-9263 / +44(0)788-561-4274, firstname.lastname@example.org / email@example.com
Eisai Files for Earlier use of Halaven® (Eribulin) for the Treatment of Metastatic Breast Cancer
Press spacebar to pause and continue. Press esc to stop.